Silence Therapeutics annual gross margin
2022
2023
2024
2025
Silence Therapeutics Gross Margin Growth & History (SLN)
Silence Therapeutics's gross margin was 61.54% for fiscal 2025.
View full Silence Therapeutics company overviewSilence Therapeutics annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 61.54% | −11.16 pp |
| 2024 | 2024-12-31 | 72.70% | +13.36 pp |
| 2023 | 2023-12-31 | 59.34% | +21.51 pp |
| 2022 | 2022-12-31 | 37.83% | — |
Silence Therapeutics quarterly gross margin
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q1 2026 | 2026-03-31 | 97.39% | +35.42 pp |
| Q4 2025 | 2025-12-31 | 64.71% | −27.24 pp |
| Q3 2025 | 2025-09-30 | 59.75% | +202.67 pp |
| Q2 2025 | 2025-06-30 | 62.05% | +402.93 pp |
| Q1 2025 | 2025-03-31 | 61.97% | −20.19 pp |
| Q4 2024 | 2024-12-31 | 91.95% | — |
| Q3 2024 | 2024-09-30 | −142.92% | — |
| Q2 2024 | 2024-06-30 | −340.87% | — |
| Q1 2024 | 2024-03-31 | 82.16% | — |
Silence Therapeutics gross margin trends
Between the periods ended 2022-12-31 and 2025-12-31, Silence Therapeutics's gross margin increased from 37.83% to 61.54%, a change of +23.71 percentage points. The latest reported quarter, Q1 2026, shows 97.39%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Silence Therapeutics source filings ↗